Table 3 Clinical trials based on immune checkpoint inhibitors (ICIs) therapy in human malignancies registered in ClinicalTrials.gov (November 2021)
From: Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Condition | Drug | Phase | Participant number | Location | Status | NCT number |
|---|---|---|---|---|---|---|
Hepatocellular carcinoma (HCC) | Camrelizumab Apatinib | 2 | 40 | China | Recruiting | NCT04826406 |
Oral squamous cell carcinoma (OSCC) | Avelumab | 2 | 240 | Italy | Recruiting | NCT04504552 |
Solid tumor Lymphoma | Nivolumab Pembrolizumab Atezolizumab Durvalumab | 2 | 40 | USA | Recruiting | NCT03544723 |
Brain cancer | Nivolumab | 2 | 180 | USA | Recruiting | NCT03173950 |
Squamous cell carcinoma of head and neck (SCCHN) | Nivolumab | 2 | 24 | USA | Recruiting | NCT03878979 |
Thymic carcinoma | KN046 | 2 | 29 | USA | Not yet recruiting | NCT04925947 |
Gastric adenocarcinoma | Nivolumab | 2 | 124 | China | Recruiting | NCT04908566 |
Cholangiocarcinoma | Lenvatinib Sintilimab | 2 | 25 | China | Not yet recruiting | NCT05010681 |
Gastric cancer Liver cancer | IMC-001 | 2 | 48 | S. Korea | Recruiting | NCT04196465 |
Non-small-cell lung carcinoma (NSCLC) | Durvalumab | 2 | 55 | USA | Recruiting | NCT04062708 |
Renal transitional cell carcinoma (TCC) | Pembrolizumab ramucirumab | 2 | 28 | USA | Recruiting | NCT04179110 |
HCC | Pembrolizumab Regorafenib | 2 | 119 | International | Recruiting | NCT04696055 |
Renal cell carcinoma (RCC) | Atezolizumab Cabozantinib | 3 | 500 | International | Recruiting | NCT04338269 |
Solid tumors | Nivolumab Pembrolizumab | 1/2 | 104 | USA Canada | Recruiting | NCT03311334 |
NSCLC Melanoma | Infliximab Vedolizumab | 1/2 | 100 | USA | Recruiting | NCT04407247 |
Pancreatic cancer | M7824 | 1/2 | 52 | USA | Recruiting | NCT04327986 |
NSCLC | Pembrolizumab | 1/2 | 30 | China | Completed | NCT04670107 |
NSCLC | Atezolizumab Tocilizumab | 1/2 | 28 | USA | Not yet recruiting | NCT04691817 |
Advanced cancers | Nivolumab Ipilimumab Pembrolizumab | 1/2 | 104 | USA | Completed | NCT02467361 |
Prostate cancer | Pembrolizumab | 2 | 100 | UK | Recruiting | NCT03506997 |
NSCLC | Atezolizumab | 2 | 21 | USA | Active, not recruiting | NCT03689855 |
Gastric carcinoma | Toripalimab | 2 | 70 | China | Not yet recruiting | NCT04891016 |
RCC | Tivozanib Nivolumab | 3 | 326 | USA | Active, not recruiting | NCT04987203 |
NSCLC | Ipilimumab Nivolumab | 3 | 1360 | France | Recruiting | NCT03469960 |
Advanced cancers | INCB086550 | 2 | 150 | Bulgaria Ukraine | Not yet recruiting | NCT04629339 |
Prostate cancer | Pembrolizumab | 2 | 33 | USA | Recruiting | NCT03406858 |
HCC | Cabozantinib | 2 | 46 | Italy | Recruiting | NCT04435977 |
Brain tumor | Pembrolizumab | 2 | 30 | USA | Recruiting | NCT04479241 |
SCCHN | Monalizumab Cetuximab | 3 | 600 | International | Recruiting | NCT04590963 |
Cervical cancer | Durvalumab | 2 | 37 | S. Korea | Not yet recruiting | NCT04800978 |
Melanoma | Nivolumab Ipilimumab | 1/2 | 72 | Australia | Recruiting | NCT03161756 |
Melanoma | Indoximod Ipilimumab Nivolumab Pembrolizumab | 1/2 | 132 | USA | Completed | NCT02073123 |
Solid tumor | Biological Nivolumab | 1/2 | 102 | USA | Recruiting | NCT04317105 |
Colorectal cancer | Atezolizumab | 2 | 52 | France | Recruiting | NCT04659382 |
Oesophageal cancer | Nivolumab Ipilimumab | 2 | 130 | France Spain | Recruiting | NCT03437200 |
HCC | Durvalumab | 2 | 37 | Hong Kong | Recruiting | NCT04913480 |
NSCLC | Camrelizumab | 2 | 62 | China | Recruiting | NCT04167774 |
Advanced cancers | Toripalimab | 2 | 35 | China | Recruiting | NCT03810339 |
Prostate cancer | Ipilimumab Nivolumab | 2 | 75 | USA | Recruiting | NCT04717154 |
NSCLC | Atezolizumab | 4 | 100 | S. Korea | Recruiting | NCT04059887 |
Pancreatic cancer | Pembrolizumab | 2 | 16 | Denmark | Recruiting | NCT04835402 |
Nasopharyngeal neoplasms | Camrelizumab | 3 | 442 | China | Recruiting | NCT03427827 |
Colorectal neoplasms Breast neoplasms | Durvalumab | 2 | 384 | USA | Recruiting | NCT02484404 |
Nasopharyngeal carcinoma | Toripalimab | 3 | 494 | China | Not yet recruiting | NCT04907370 |
Mesothelioma | Durvalumab | 3 | 480 | International | Recruiting | NCT04334759 |
Immune-mediated colitis | Tofacitinib | 2 | 10 | Canada | Not yet recruiting | NCT04768504 |
Anal cancer | Durvalumab | 2 | 178 | Germany Switzerland | Recruiting | NCT04230759 |
Metastatic solid tumor | Cemiplimab | 2 | 38 | Netherlands | Not yet recruiting | NCT04706715 |
Hepatocellular carcinoma Colorectal neoplasms Gastric cancer Lung cancer | Nivolumab pembrolizumab | 2 | 80 | USA | Recruiting | NCT03259867 |
Nasopharyngeal carcinoma | Durvalumab | 2 | 118 | Hong Kong | Recruiting | NCT04447612 |
NSCLC | Camrelizumab | 2 | 40 | China | Recruiting | NCT04541251 |
Esophageal cancer Metastatic cancer Squamous cell carcinoma | Cabozantinib atezolizumab | 2 | 37 | Taiwan | Recruiting | NCT05007613 |
Cervical cancer | Atezolizumab | 2 | 189 | France | Recruiting | NCT03612791 |
Pancreatic cancer | Pembrolizumab | 2 | 24 | USA | Completed | NCT03331562 |
Nasopharyngeal carcinoma | Toripalimab | 2 | 126 | China | Recruiting | NCT04517214 |
Breast cancer | Pembrolizumab | 2 | 46 | Germany | Recruiting | NCT03988036 |
Breast cancer | Pembrolizumab | 2 | 15 | Israel | Recruiting | NCT03591276 |
Solid tumors | Ipilimumab nivolumab pembrolizumab atezolizumab | 2 | 60 | USA | Recruiting | NCT03693014 |
Gastrointestinal cancer | Atezolizumab | 2 | 175 | USA | Recruiting | NCT04214418 |
Breast cancer | Nivolumab | 2 | 90 | S. Korea | Recruiting | NCT04061863 |
Solid tumors | Ipilimumab Nivolumab Pembrolizumab Atezolizumab Avelumab Durvalumab Cemiplimab | 2 | 126 | Netherlands | Recruiting | NCT04954599 |
NSCLC | Pembrolizumab | 2 | 85 | USA | Recruiting | NCT03233724 |